Clinical Trial Update: Safety and Efficacy of TULY (Rasburicase) in Prevention and Treatment of Malignancy-associated Hyperuricemia [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the safety and efficacy of rasburicase (TULY) for prevention and treatment of malignancy-associated hyperuricemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperuricemia
• Tumor Lysis Syndrome

Drugs mentioned

• Rasburicase (rasburicase)

Snippet

Sponsor: Virchow Group | Conditions: Hyperuricemia | Phase 3 | Status: COMPLETED